Literature DB >> 25771096

The epigenetic/noncoding origin of tumor dormancy.

Francesco Crea1, Nur Ridzwan Nur Saidy2, Colin C Collins3, Yuzhuo Wang4.   

Abstract

Cancer stem cells (CSCs) have been implicated as the seeds of treatment resistance and metastasis, which are the most deadly features of a neoplasm. However, an unequivocal definition of the CSC phenotype is still missing. A common feature of normal and aberrant stem cells is their ability to enter a prolonged dormant state. Cancer dormancy is a key mechanism for treatment resistance and metastasis. Here we propose a unified definition of dormancy-competent CSCs (DCCs) as the neoplastic subpopulation that can plastically alternate periods of dormancy and rapid growth. Irreversible DNA mutations can hardly account for this versatile behavior, and based on emerging evidence we propose that cancer dormancy is a nongenetic disease driven by the flexible nature of the epigenetic/noncoding interactome.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  dormancy; dormancy-competent cancer stem cells; epigenetic/noncoding interactome; metastasis; therapy resistance

Mesh:

Year:  2015        PMID: 25771096     DOI: 10.1016/j.molmed.2015.02.005

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  22 in total

Review 1.  The biology and clinical implications of prostate cancer dormancy and metastasis.

Authors:  Colm Morrissey; Robert L Vessella; Paul H Lange; Hung-Ming Lam
Journal:  J Mol Med (Berl)       Date:  2015-10-21       Impact factor: 4.599

2.  The induction of MIG6 under hypoxic conditions is critical for dormancy in primary cultured lung cancer cells with activating EGFR mutations.

Authors:  H Endo; J Okami; H Okuyama; Y Nishizawa; F Imamura; M Inoue
Journal:  Oncogene       Date:  2016-11-28       Impact factor: 9.867

3.  Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis.

Authors:  W-Y Chen; Y-C Tsai; M K Siu; H-L Yeh; C-L Chen; J J Yin; J Huang; Y-N Liu
Journal:  Oncogene       Date:  2017-07-10       Impact factor: 9.867

Review 4.  Tumor dormancy as an alternative step in the development of chemoresistance and metastasis - clinical implications.

Authors:  Federico Rossari; Cristina Zucchinetti; Gabriele Buda; Enrico Orciuolo
Journal:  Cell Oncol (Dordr)       Date:  2019-08-07       Impact factor: 6.730

Review 5.  Novel Insights on Lipid Metabolism Alterations in Drug Resistance in Cancer.

Authors:  Ruixue Yang; Mei Yi; Bo Xiang
Journal:  Front Cell Dev Biol       Date:  2022-05-13

Review 6.  The dormant cancer cell life cycle.

Authors:  Tri Giang Phan; Peter I Croucher
Journal:  Nat Rev Cancer       Date:  2020-06-02       Impact factor: 60.716

Review 7.  The role of RNA processing and regulation in metastatic dormancy.

Authors:  Kimberly A Parker; Nathaniel J Robinson; William P Schiemann
Journal:  Semin Cancer Biol       Date:  2021-03-26       Impact factor: 15.707

8.  Monitoring cancer stem cells: insights into clinical oncology.

Authors:  ShuChen Lin; YingChun Xu; ZhiHua Gan; Kun Han; HaiYan Hu; Yang Yao; MingZhu Huang; DaLiu Min
Journal:  Onco Targets Ther       Date:  2016-02-11       Impact factor: 4.147

Review 9.  Tumor Dormancy: Implications for Invasion and Metastasis.

Authors:  Georgia Gomatou; Nikolaos Syrigos; Ioannis A Vathiotis; Elias A Kotteas
Journal:  Int J Mol Sci       Date:  2021-05-04       Impact factor: 5.923

10.  Melanoma dormancy in a mouse model is linked to GILZ/FOXO3A-dependent quiescence of disseminated stem-like cells.

Authors:  Yasmine Touil; Pascaline Segard; Pauline Ostyn; Severine Begard; Caroline Aspord; Raja El Machhour; Bernadette Masselot; Jerome Vandomme; Pilar Flamenco; Thierry Idziorek; Martin Figeac; Pierre Formstecher; Bruno Quesnel; Renata Polakowska
Journal:  Sci Rep       Date:  2016-07-28       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.